Becton Dickinson to acquire CR Bard for $24 billion

Medical equipment giant Becton, Dickinson and Co. (BD) is getting bigger, announcing a $24 billion cash-and-stock deal to acquire CR Bard, including its portfolio in oncology, vascular and surgical products.

A press release from BD said the boards of both companies unanimously approved the transaction and expect it to close in the fall of 2017.

“The combination will create a highly differentiated medical technology company uniquely positioned to improve both the process of care and the treatment of disease for patients and healthcare providers,” the release said. “The transaction will build on BD’s leadership position in medication management and infection prevention with an expanded offering of solutions across the care continuum. Additionally, Bard’s strong product portfolio and innovation pipeline will increase BD’s opportunities in fast-growing clinical areas, and the combination will enhance growth opportunities for the combined company in non-U.S. markets.”

The acquisition is the largest so far in 2017 in the U.S., according to Dealogic. Combined, the companies would have 65,000 employees and about $16 billion in annual revenue.

Among the strategic benefits of the deal highlighted by BD, it mentioned Bard’s peripherally inserted central catheters, midlines and drug delivery ports, offering a more comprehensive range of products “positioned to address 75 percent of the most costly and frequent healthcare-associated infections.”

The deal may also help sales of BD’s last big acquisition, CareFusion, which it purchased in 2014 for $12 billion.

On the same day the CR Bard deal was announced, BD also appointed Tom Polen as its new president, with his duties including overseeing operations of the new interventional segment which will include the CR Bard business.

"This is an exciting time for BD,” Polen said in a statement. “I am honored to serve in this new role as we continue our transformation into a medical technology leader focused on delivering solutions that advance the discovery, diagnostics and delivery of health care globally and helping health care providers worldwide to improve both the process of care and the treatment of disease."

""
John Gregory, Senior Writer

John joined TriMed in 2016, focusing on healthcare policy and regulation. After graduating from Columbia College Chicago, he worked at FM News Chicago and Rivet News Radio, and worked on the state government and politics beat for the Illinois Radio Network. Outside of work, you may find him adding to his never-ending graphic novel collection.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.